The application of genetically engineered herpes simplex viruses to the treatment of experimental brain tumors
about
Expression of RNA interference triggers from an oncolytic herpes simplex virus results in specific silencing in tumour cells in vitro and tumours in vivo.Recombinant oncolytic poliovirus eliminates glioma in vivo without genetic adaptation to a pathogenic phenotype.Attenuated, replication-competent herpes simplex virus type 1 mutant G207: safety evaluation in miceAttenuated, replication-competent herpes simplex virus type 1 mutant G207: safety evaluation of intracerebral injection in nonhuman primates.A herpes simplex virus type 1 gamma34.5 second-site suppressor mutant that exhibits enhanced growth in cultured glioblastoma cells is severely attenuated in animalsOncolytic viruses as novel anticancer agents: turning one scourge against another.Preparing an oncolytic poliovirus recombinant for clinical application against glioblastoma multiformeRegulation of herpes simplex virus gamma(1)34.5 expression and oncolysis of diffuse liver metastases by Myb34.5.Transcriptional control of viral gene therapy by cisplatinGene targets of antisense therapies in breast cancer.Multimutated herpes simplex virus g207 is a potent inhibitor of angiogenesis.Serial passage through human glioma xenografts selects for a Deltagamma134.5 herpes simplex virus type 1 mutant that exhibits decreased neurotoxicity and prolongs survival of mice with experimental brain tumors.Engineered herpes simplex virus expressing IL-12 in the treatment of experimental murine brain tumors.Replication of herpes simplex virus 1 depends on the gamma 134.5 functions that facilitate virus response to interferon and egress in the different stages of productive infection.Genetically engineered herpes simplex viral vectors in the treatment of brain tumors: a review.Development of recombinant vesicular stomatitis viruses that exploit defects in host defense to augment specific oncolytic activity.Oncolytic herpes viruses as a potential mechanism for cancer therapy.Neutralizing innate host defenses to control viral translation in HSV-1 infected cells.Combination of a fusogenic glycoprotein, pro-drug activation and oncolytic HSV as an intravesical therapy for superficial bladder cancerIncreased efficacy of an interleukin-12-secreting herpes simplex virus in a syngeneic intracranial murine glioma modelConditionally replicative adenovirus for gastrointestinal cancers.Oncolytic viral therapies.Effect of γ34.5 deletions on oncolytic herpes simplex virus activity in brain tumors.The range and distribution of murine central nervous system cells infected with the gamma(1)34.5- mutant of herpes simplex virus 1.Transcription of the derepressed open reading frame P of herpes simplex virus 1 precludes the expression of the antisense gamma(1)34.5 gene and may account for the attenuation of the mutant virusGene therapy applications of viral vectors.Preclinical evaluation of a genetically engineered herpes simplex virus expressing interleukin-12The Herpes Simplex Virus Neurovirulence Factor γ34.5: Revealing Virus-Host Interactions.Oncolytic viruses for cancer therapy II. Cell-internal factors for conditional growth in neoplastic cells.To replicate or not to replicate: achieving selective oncolytic virus replication in cancer cells through translational control.Oncolytic potential of rodent parvoviruses for cancer therapy in humans: a brief review.Herpes simplex virus 1 (HSV-1) for cancer treatment.Preclinical evaluation of oncolytic δγ(1)34.5 herpes simplex virus expressing interleukin-12 for therapy of breast cancer brain metastasesDesign of a Phase I Clinical Trial to Evaluate M032, a Genetically Engineered HSV-1 Expressing IL-12, in Patients with Recurrent/Progressive Glioblastoma Multiforme, Anaplastic Astrocytoma, or Gliosarcoma.Preclinical evaluation of herpes simplex virus armed with granulocyte-macrophage colony-stimulating factor in pancreatic carcinomaFeasibility of herpes simplex virus type 1 mutants labeled with radionuclides for tumor treatment.Enhanced antitumor efficacy of a herpes simplex virus mutant isolated by genetic selection in cancer cellsThe function of herpes simplex virus genes: a primer for genetic engineering of novel vectorsClinical development directions in oncolytic viral therapy.Rethinking herpes simplex virus: the way to oncolytic agents.
P2860
Q33690926-2D2C0416-091B-41F6-80F1-6978EA5B7872Q33797119-0310B303-B9EB-470E-BFA4-2AEDD5F39327Q33802747-1DD4F8BB-3DC4-40F4-82D5-5B6890EE209FQ33816579-0D7A053B-FD26-40D7-A3A0-CE231273CA18Q33851852-A5B81F29-C6FD-438C-BAEC-B53C8D2D9B80Q34074708-F433913A-9959-4F37-9A74-44E76C00CFC8Q34105106-9BD5E650-9731-408C-9D0C-C755B3A7CD4EQ34790267-84046FAB-DE6C-44C2-8959-C204C501FE24Q34795177-8D628B53-166A-4E67-A4D7-8296E3E0BDBCQ34837459-E2376E2C-3FAA-4873-A77F-523A4D6D74B8Q34928710-F4787E70-75C7-481F-8704-E0E152FEFD92Q35023693-2711FBF0-A4AA-4711-B52B-043B45921084Q35051285-36750606-8A00-47BB-92F5-0389115D99D1Q35123297-442F3375-5EE2-42BF-AFD9-F49CAF20200CQ35126267-415818C2-715A-4431-AD01-D166E9AD17C7Q35182301-18585A9B-B9C7-4E90-8C31-CB6B03A80EB5Q35613495-05BE0767-C7C8-4C19-ACAC-7476A0CE8F64Q35613824-C817C29C-99EF-40FA-9D63-B7BE12718FDCQ35739482-B734B6B1-D009-46EC-AA75-728C07A47596Q35800497-EA38D884-A3F4-4F8F-863D-1E05F8E916C9Q35842604-512AB8BC-2539-4DBF-AA5E-5F832A20BF9FQ35852258-C0C3AB36-D7B4-4302-9016-247742E0B145Q35867997-37B4FE82-F408-4669-BC01-167CBB987100Q35888685-9A985ABD-0481-465D-9C71-68D22CB0BF29Q35895914-D838FBB5-5784-419A-8CB7-A742EBEA6757Q35904004-5E5AD2A4-CAAC-44C8-B5D8-3938CFC38EECQ35943736-18BE09A7-237F-409D-824C-E7A175CC89ABQ35952866-CEA91201-6411-4148-B96E-28B33981B120Q36102568-E968FDB2-B448-4197-BABE-C3BECC13EF9DQ36318160-18E9995D-A178-4CAD-8A5A-E1E9A118CB7EQ36326291-A06C5314-49C7-4521-80A4-3385299834A5Q36444443-0C49B155-7ECE-4B28-BDA7-F714916836FFQ36546412-F413AC36-DA90-4F29-B4B8-E844D7F791C0Q37064326-905D61B9-5DE3-44D2-8D8C-7ED6A3AB3285Q37102488-A2FA22E1-CC8A-402F-9E09-B6AADB09F47EQ37103315-9C8E25AF-2F26-445E-AA86-89EB98F45714Q37116149-5751CC55-7DAC-4A65-A7AA-D1BC7929DDEDQ37247688-1259C4B4-19C2-4106-B79C-206F33B43DC9Q37857659-3056D9C5-F884-4680-94BA-7A3AE8C4DD56Q37882608-20EDE22B-E523-4094-8F8B-940EF9C186D6
P2860
The application of genetically engineered herpes simplex viruses to the treatment of experimental brain tumors
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on October 1996
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
The application of genetically ...... t of experimental brain tumors
@en
The application of genetically ...... of experimental brain tumors.
@nl
type
label
The application of genetically ...... t of experimental brain tumors
@en
The application of genetically ...... of experimental brain tumors.
@nl
prefLabel
The application of genetically ...... t of experimental brain tumors
@en
The application of genetically ...... of experimental brain tumors.
@nl
P2093
P2860
P356
P1476
The application of genetically ...... t of experimental brain tumors
@en
P2093
G Y Gillespie
L Soroceanu
R J Whitley
S S Andreansky
P2860
P304
11313-11318
P356
10.1073/PNAS.93.21.11313
P407
P577
1996-10-01T00:00:00Z